Rightway offers access to generic drugs offered by Cost Plus Drug through its mobile app.
Mark Cuban Cost Plus Drug Company has added Rightway to its network. The relationship grants members of Rightway’s PBM direct access to all medications available through Cost Plus Drug through its mobile app.
“Cost Plus Drugs offers some of the lowest prices in the market,” Scott Musial, chief pharmacy officer of Rightway, said in a press release. “It enables Rightway to step away from the traditional supply chain, offering our members greater choice, lowering their spending, and giving them back time they’d spend at the pharmacy.”
Rightway calls itself a “care navigation” company that includes a PBM platform that members can access through a mobile app. The PBM provides pass-through pricing and personalized clinical management.
The company’s pharmacists will identify members, such as those with chronic conditions, who may benefit from the service with Cost Plus Drugs and help them transfer their medications if they choose to do so. Rightway’s health guides will assist any members interested in transferring their medications, from answering their questions to coordinating with healthcare providers.
Mark Cuban Cost Plus Drug Company launched in January 2022 to provide lower-cost generic medications. medications are priced at cost with a 15% markup The direct-to-consumer pharmacy now carries almost 1,000 medications.
Rightway also recently launched RightwayHub to streamline access to digital healthcare solutions. The program brings together a range of vetted programs across condition areas including musculoskeletal health, behavioral health, and chronic care management. The hub includes 10 solutions.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Humira Biosimilars Have a Slow Uptake, Finds Samsung Bioepis Report
April 8th 2024Caps on Medicare Part D cost sharing as a result of the Inflation Reduction Act, could reduce members’ financial incentive for switching to a biosimilar, suggests the newest Samsung Bioepis Quarterly Biosimilar Market Report.